USPTO serial 79188650
ANEMOCYTE
Reviewed by CopyMark Law Group
Reg. 5215720Status 706Renewal
- Filing date
- Status date
- Registration date
- Jun 6, 2017
- Examiner
- SAUNDERS, ANDREA DAWN
- Law office
- TMO LAW OFFICE 137
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with ANEMOCYTE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*
Plus Government fees of $1,950
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Brian A. Tollefson
Brian A. Tollefson Tollefson IP326 First Street, Suite 202Annapolis, MD 21403United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary preparations, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for use in human [ and veterinary ] medicine; chemical preparations for pharmaceutical or medical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets, syringes, infusion bags, vials and pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, nk cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, products for gene therapy, namely, genetically modified cells, viral vectors, nucleic acids; tissue engineered products, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace or restore a lost or impaired tissue or function; products for regenerative medicine, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace, restore or promote the repair, replacement or regeneration of a lost or impaired tissue or function; products for personalized medicine made of autologous cells or proteins or nucleid acids derived from individual genomic sequences; preparations made up of cells for medical or clinical use; preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes; preparations made up of tissues, namely, biological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy | ACTIVE | — |
| 010 | [ Surgical apparatus and instruments for medical, dental and veterinary use; medical devices for the introduction of pharmaceutical preparations in the human body, in particular syringes and catheters; medical equipment, namely, centrifuges or other separation devices for the isolation of cell sub-populations from tissues and biopsies; surgical apparatus and instruments for medical and veterinary purpose; electrical medical instruments for use in electroporation of cells and tissues for gene transfer purposes, both in vivo and ex-vivo; electronic medical instruments for use in imaging for diagnostic purposes or for monitoring of vital signs of patients ] | ACTIVE | — |
| 042 | Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; Providing medical and scientific research information and data on developments in the medical and veterinary fields; scientific and technological services, namely, scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; consultancy to ensure compliance with quality standards and the design and validation of manufacturing processes in the scientific field and medical technology fields | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ANEMOCYTE S.R.L.
- Other trademarks owned by ARETA INTERNATIONAL S.R.L.
- Other trademarks owned by ARETA INTERNATIONAL S.R.L.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named ANEMOCYTE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 6, 2026 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Jun 4, 2026 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| May 12, 2026 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| May 12, 2026 | INPC | INVALIDATION PROCESSED | — |
| Mar 26, 2026 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Oct 28, 2025 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Sep 30, 2025 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jul 3, 2025 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Feb 28, 2025 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Feb 28, 2025 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Nov 15, 2024 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Oct 25, 2024 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Aug 21, 2024 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Feb 24, 2024 | PR71 | POST REGISTRATION ACTION MAILED - SEC.71 | — |
| Feb 12, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jun 5, 2023 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Oct 24, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 24, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 24, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Oct 24, 2022 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Oct 24, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 24, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 24, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 6, 2022 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Apr 9, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 22, 2018 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Oct 28, 2017 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 14, 2017 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 14, 2017 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 6, 2017 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 6, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 21, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 21, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 17, 2017 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 1, 2017 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 1, 2017 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 1, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 14, 2017 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 1, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 1, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 1, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 1, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 1, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 1, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 1, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 1, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 1, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 8, 2017 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 8, 2017 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 8, 2017 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 22, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 22, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 7, 2016 | ALIE | ASSIGNED TO LIE | — |
| Nov 16, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 11, 2016 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 11, 2016 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 29, 2016 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 13, 2016 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 13, 2016 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 12, 2016 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 12, 2016 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 11, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 8, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 8, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 7, 2016 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |